Algeta ASA : Algeta ASA : Proposal from the Nomination Committee to the Annual General Meeting on 11 April 2013

Algeta ASA : Algeta ASA : Proposal from the Nomination Committee to the Annual
                       General Meeting on 11 April 2013

To the Shareholders of Algeta ASA

Reference is made to the announcement of 19 March 2013 regarding Algeta  ASA's 
Annual General Meeting  2013 and agenda  item 13: Election  of members to  the 
Board of Directors. At the time of the announcement, the Nomination  Committee 
had not decided on its proposal for new members of the Board of Directors. The
Nomination Committee has  now made  its decision  - please  find the  proposal 


For further information, please contact:

Mike Booth / Renate Birkeli        +47 23 00 67 32
Communications & Corporate Affairs
Media enquiries:
Mark Swallow                       +44 207 638 9571
Citigate Dewe Rogerson   
Knut Ekern                         +47 22 04 82 00
Gambit Hill & Knowlton   
US investor enquiries:
Tricia Swanson                     +1 646 378 2953
The Trout Group          

About Algeta

Algeta is  a  company focused  on  developing novel  targeted  therapies  for 
patients with cancer based on  its alpha-pharmaceutical platform. The  Company 
is headquartered in  Oslo, Norway, and  has a US  subsidiary, Algeta US,  LLC, 
based in Cambridge, MA performing  commercial marketing operations in the  US. 
Algeta is  listed  on the  Oslo  Stock  Exchange (Ticker:  ALGETA).  For  more 
information please visit

Forward-looking Statements

This news release contains certain  forward-looking statements that are  based 
on uncertainty, as they relate to events and depend on circumstances that will
occur in the future and which, by their nature, may have an impact on  results 
of operations  and the  financial condition  of Algeta.  Such  forward-looking 
statements reflect  our  current  views  and  are  based  on  the  information 
currently available to Algeta. Algeta cannot give any assurance as to  whether 
such forward  looking  statements will  prove  to be  correct.  These  forward 
looking statements include statements  regarding interactions with  regulatory 
authorities, our anticipated co-promotion of radium-223 in the US,  additional 
clinical development of radium-223 and our TTC program. There are a number  of 
factors that could cause actual results and developments to differ  materially 
from those expressed  or implied  by these  forward-looking statements.  These 
factors include, among  other things, risks  or uncertainties associated  with 
the success of future clinical trials, collaborations with other companies  in 
the development of  targeting molecules, the  ability to identify  and hire  a 
sufficient number  of  qualified employees  for  the US  field  force,  growth 
management,  general  economic  and   business  conditions  and  the   pricing 
environment,  the  impact   of  competition,  the   ability  to   successfully 
commercialize  radium-223  and  our  other  products,  the  risk  that   costs 
associated  with  the   co-promotion  of  radium-223   may  be  greater   than 
anticipated, the risk that research & development will not yield new  products 
that  achieve  commercial  success,   manufacturing  capacity,  the  risk   of 
non-approval of  patents  not  yet  granted,  risks  in  obtaining  regulatory 
approvals for radium-223 and our other products and difficulties of  obtaining 
relevant governmental  approvals for  new products,  and the  other risks  and 
uncertainties described in our annual report.

This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
Proposal from the Nomination Committee to the AGM 2013


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: Algeta ASA via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.